<DOC>
	<DOC>NCT01647893</DOC>
	<brief_summary>A Phase 1 Clinical Study, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study of the Safety and Pharmacokinetic/Pharmacodynamic Profiles of CTB-001 Intravenously Administered in Healthy Male Subjects</brief_summary>
	<brief_title>Phase 1 Single Dose Escalation Study of CTB-001</brief_title>
	<detailed_description />
	<mesh_term>Mannitol</mesh_term>
	<criteria>Adult males aged 20 to 40 years at screening. Be able to understand the objective, method of the study, the characteristics of investigational drug, and comply with the requirement of the study. Subject must provide written informed consent prior to study participation. History or presence of liver, kidney, or nervous system disease, respiratory disorders, endocrinological disorders, hematooncologic, cardiovascular or psychiatric or cognitive disorders. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or disorders of absorption, distribution, metabolism, excretion. History of known hypersensitivity to drugs including CTB001</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>